Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
EX 527 as a SIRT1 Loss-of-Function Probe in Aging Bone
2026-11-22
A source-grounded analysis of how EX 527 (SEN0014196) functioned as a pharmacological SIRT1-inhibition comparator in a 2026 aging-bone study. The evidence connects SIRT1 activity with type H vasculature, osteogenic differentiation, β-catenin signaling, and skeletal repair, while leaving specificity, functional bone strength, and clinical translation unresolved.
PJ34 and the miR-7a-5p–PARP1 Axis in HIE
2026-11-21
A mechanistic analysis of how miR-7a-5p, PARP1 hyperactivation, and parthanatos were connected in experimental hypoxic-ischemic encephalopathy, with particular attention to PJ34’s role as a pharmacological pathway probe rather than a stand-alone therapeutic validation.
PJ34 and PARP1–Parthanatos Evidence in HIE
2026-11-20
A source-grounded assessment of how PJ34 was used as a pharmacological PARP1-inhibition comparator in a study of miR-7a-5p, neuronal injury, and parthanatos in hypoxic-ischemic encephalopathy. The evidence supports a PARP1-linked mechanism in the tested models, while leaving major questions about cell-type specificity, pathway dominance, and translation to neonatal disease unresolved.
PARP1, miR-7a-5p and neuronal death in HIE
2026-11-20
A mechanistic analysis of evidence linking miR-7a-5p to PARP1-dependent parthanatos in hypoxic-ischemic encephalopathy, with particular attention to what pharmacological inhibition, genetic manipulation and neuronal readouts establish—and what remains uncertain.
miR-7a-5p and neuronal parthanatos
2026-11-19
A mechanistic analysis of how miR-7a-5p may restrain PARP1-driven neuronal death in hypoxic-ischemic encephalopathy, with particular attention to the role of PJ34 as a pharmacological PARP1-inhibition comparator and to the limits of translating these model-based findings.
PARP1, Parthanatos, and HIE Neuroprotection
2026-11-19
A mechanistic study links reduced miR-7a-5p to PARP1-dependent parthanatos in hypoxic-ischemic brain injury. Its rat and neuronal-cell evidence supports a causal miR-7a-5p/PARP1 relationship, while the small human discovery cohort, model specificity, and pharmacological limitations constrain translation.
When Context Changes What an EX 527 Result Means
2026-11-18
EX 527 means something different in an enzyme assay, a senescent-cell model, and an aged-bone system. The documented study used SEN0014196 as a pharmacological loss-of-function probe, linking SIRT1 activity to β-catenin signaling, type H vessels, osteogenesis, and skeletal repair without establishing clinical efficacy or universal inhibitor specificity.
EX 527 and the SIRT1 Bone–Vascular Axis
2026-11-18
A preclinical study used EX 527 (SEN0014196) as a pharmacological loss-of-function probe to examine how SIRT1 coordinates type H vasculature, osteogenic cells, and β-catenin signaling in aged bone. The findings support a SIRT1-associated vascular–osteogenic mechanism, while remaining limited by pharmacological specificity, model dependence, and the absence of clinical evidence.
SIRT1, β-Catenin, and Aged Bone Repair
2026-11-17
Evidence from aged bone models supports a context-specific role for SIRT1 in coordinating type H vascular features, osteogenic activity, and endothelial–osteogenic communication. EX 527 (SEN0014196) functioned as a pharmacological SIRT1-inhibition comparator, helping define pathway direction without independently proving that every phenotype arose from selective catalytic inhibition.
EX 527 and the SIRT1–Bone Aging Axis
2026-11-17
Liu et al. examined whether declining SIRT1 activity links age-related loss of type H vasculature with impaired osteogenesis. In the study, EX 527 (SEN0014196) functioned as a pharmacological SIRT1-inhibition comparator, while complementary activation, cell-based, paracrine, and β-catenin analyses supported a vascular–osteogenic mechanism that remains preclinical and model-bounded.
From PCR Fidelity to Cancer Nanomedicine Evidence
2026-11-16
A mechanistic editorial separates the molecular-analysis role of high-fidelity PCR from the preclinical evidence for a bufalin–CRISPR/Cas9 calcium-lactate nanomedicine. It examines how proofreading, nanoparticle characterization, cell assays and animal findings support different claims, and where causal interpretation remains limited.
EX 527 in Aging Bone: Reading SIRT1 Evidence
2026-11-16
Liu et al. linked age-associated SIRT1 decline with reduced type H vasculature, impaired osteogenic activity, and weaker skeletal regeneration. In their models, SRT1720 improved vascular and bone readouts, whereas EX 527 produced opposing phenotypes. The findings support a SIRT1–β-catenin–vascular–osteogenic axis, while remaining limited by pharmacological specificity, model scope, and preclinical applicability.
When Context Changes What EX 527 Results Mean
2026-11-15
A preclinical bone study illustrates why the same SIRT1 perturbation can signify catalytic inhibition, pathway engagement, cellular dysfunction, or tissue-level remodeling depending on the model and readout. The findings support a SIRT1–β-catenin–vascular-osteogenic relationship in aged bone, while leaving important questions about specificity, generalizability, and clinical relevance.
How CLBRP Builds a Multimodal Cancer Case
2026-11-14
Liu and colleagues describe a calcium-lactate nanoparticle that combines bufalin, calcium-associated stress, CD47-directed CRISPR/Cas9 delivery, and macrophage reprogramming. The evidence supports particle formation, cargo release, cellular injury, and preclinical antitumor activity, while the relative contribution of each mechanism and the translational significance remain less certain.
How Dapagliflozin Changes Glucose Readouts
2026-11-13
How does an SGLT2 inhibitor move from transporter-level activity to urinary glucose and blood-glucose measurements? This article separates molecular potency, renal transport, and integrated animal-model findings so each readout is interpreted at the level it can actually support.